HISTOPATHOLOGICAL RESPONSE TO FOLFOXIRI PLUS BEVACIZUMAB OF LIVER METASTASES FROM COLORECTAL CANCER

被引：0
|
作者：
Caparello, Chiara [1 ]
Loupakis, Fotios [1 ]
Schirripa, Marta [1 ]
Funel, Niccola
Pollina, Luca [2 ]
Vasile, Enrico [1 ]
Cremolini, Chiara [1 ]
Salvatore, Lisa [1 ]
Masi, Gianluca [1 ]
Fornaro, Lorenzo [1 ]
Campani, Daniela
Falcone, Alfredo [3 ]
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[2] Azienda Osped Univ Pisana, Dipartimento Med Lab & Diagnosi Mol, Pisa, Italy
[3] Univ Pisa, Dept Oncol Transplants & New Technol Med, Pisa, Italy
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v95 / v95
页数：1
相关论文
共 50 条
  • [1] Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer.
    Schirripa, M.
    Loupakis, F.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Fornaro, L.
    Campani, D.
    Falcone, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    F Loupakis
    M Schirripa
    C Caparello
    N Funel
    L Pollina
    E Vasile
    C Cremolini
    L Salvatore
    M Morvillo
    C Antoniotti
    F Marmorino
    G Masi
    A Falcone
    [J]. British Journal of Cancer, 2013, 108 : 2549 - 2556
  • [3] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    Loupakis, F.
    Schirripa, M.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Morvillo, M.
    Antoniotti, C.
    Marmorino, F.
    Masi, G.
    Falcone, A.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2549 - 2556
  • [4] FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Modest, D. P.
    Neumann, U. P.
    Pratschke, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 73 : 71 - 73
  • [5] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [6] Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
    Bibeau, F.
    Gil, H.
    Castan, F.
    Boissiere-Michot, F.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3127 - 3129
  • [7] Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’
    F Bibeau
    H Gil
    F Castan
    F Boissière-Michot
    [J]. British Journal of Cancer, 2013, 109 : 3127 - 3129
  • [8] Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
    Schirripa, M.
    Loupakis, F.
    Pollina, L.
    Cremolini, C.
    Pasquini, G.
    Falcone, A.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3129 - 3130
  • [9] Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab’
    M Schirripa
    F Loupakis
    L Pollina
    C Cremolini
    G Pasquini
    A Falcone
    [J]. British Journal of Cancer, 2013, 109 : 3129 - 3130
  • [10] Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer.
    Shimada, M.
    Nishioka, M.
    Hanaoka, J.
    Mori, H.
    Ikemoto, T.
    Imura, S.
    Morine, Y.
    Utsunomiya, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345